- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03077295
The Big Breakfast Study
Role of Breakfast Size and Composition for Appetite Control and Energy Balance
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The aim of this study is to further strengthen our understanding of the role of dietary components (in particular fibre and protein) in a healthy diet. The information gained from this research will lead to better policy advice, particularly in relation to healthy weight management, metabolic control, mental health and intestinal health. It will also lay the foundations to produce healthier primary products and aid the food industry in developing new and healthier products (e.g. products that aid hunger control and satiety). This will be addressed through four interlinked objectives:
O1: Healthy weight management and improved metabolic and mental health O2: Identification of gut bacteria and compounds of relevance to vascular and gut health O3: Linking fibre consumption to intestinal microbial communities and health O4: Mathematical modelling of interactions between diet and gut microbial communities
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Aberdeen, Storbritannia, AB25 2ZD
- The Rowett Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- BMI ranging from 27-42 kg/m2;
- those habitually consuming breakfast (at least 5 times a week).
Exclusion Criteria:
- women who are pregnant, planning to be pregnant or breastfeeding
- subjects with food allergy
- diagnosis of diabetes, hypertension, renal, hepatic, haematological disease or coronary heart disease
- having given a pint of blood for transfusion purposes within the last month
- unsuitable veins for blood sampling
- inability to understand the participant information sheet
- inability to speak, read and understand the English language
- those on any prescription medications (other than oral contraceptives)
- those on any specific diet regimes
- those on any weight loss programmes (that may be affecting lifestyle, physical activity and diet).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: High Fibre to High-Protein (HF-HP)
|
High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch.
Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g.
wheat bran, fava bean, lentil, buckwheat).
Andre navn:
• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch.
Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy.
Total dietary fibre will be no more than 15g/d for 2000kcal intake.
Andre navn:
|
|
Eksperimentell: High Protein to High-Fibre (HP-HF)
|
High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch.
Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g.
wheat bran, fava bean, lentil, buckwheat).
Andre navn:
• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch.
Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy.
Total dietary fibre will be no more than 15g/d for 2000kcal intake.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Energy Balance
Tidsramme: measured up to day 71 of study
|
Chronic influence on energy balance (body weight, kg)
|
measured up to day 71 of study
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Acute effects on appetite after test meals
Tidsramme: Baseline & week 4 of each treatment
|
Appetite questionnaires recorded on Visual Analogue Scales every 30mins on test days
|
Baseline & week 4 of each treatment
|
|
Acute effects on biomarkers of health after test meals
Tidsramme: Baseline & week 4 of each treatment
|
blood samples analysed for Glucose, Lipids and Hormones
|
Baseline & week 4 of each treatment
|
|
Acute effects on gastric emptying after test meals
Tidsramme: Baseline & week 4 of each treatment
|
gastric emptying (stable isotope, Octanoic acid labelled breath samples)
|
Baseline & week 4 of each treatment
|
|
Resting Metabolic Rate (RMR) before & after test meals
Tidsramme: Baseline & week 4 of each treatment
|
Chronic influence on metabolism or Thermic Effect of Food (TEF) using indirect calorimetry measurement
|
Baseline & week 4 of each treatment
|
|
Faecal sample analysis for gut health
Tidsramme: up to 10 weeks
|
Chronic influence on changes in gut microbiota
|
up to 10 weeks
|
|
Bone Density
Tidsramme: Baseline & week 4 of each treatment
|
Dual Energy X-ray Absorptiometry (DXA) Scan to measure fat mass, fat free mass & bone density as part of the 4 compartment model
|
Baseline & week 4 of each treatment
|
|
Body Composition
Tidsramme: Baseline & week 4 of each treatment
|
Air Displacement Plethysmography (BodPod) to measure body fat as part of the 4 compartment model
|
Baseline & week 4 of each treatment
|
|
Total Body Water
Tidsramme: Baseline & week 4 of each treatment
|
Deuterium Dilution to measure Total Body Water (TBW) as part of the 4 compartment model
|
Baseline & week 4 of each treatment
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Alexandra Johnstone, PhD, Senior Research Fellow
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 804
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .